Ciclesonide nasal spray

Product:
CICLESONIDE (Omnaris®) nasal spray

Class of drugs:
Topical corticosteroid

Indication:
Treatment of allergic rhinitis

Manufacturer:
Nycomed Canada Inc.

Highlights of Recommendation:

- Ciclesonide (Omnaris) is a corticosteroid nasal spray indicated for the treatment of seasonal and perennial allergic rhinitis.
- The Committee reviewed six randomized controlled studies comparing ciclesonide (Omnaris) to placebo in patients with seasonal or perennial allergic rhinitis. Compared with patients on placebo, those treated with ciclesonide (Omnaris) achieved slightly greater symptom relief. The Committee questioned whether the small improvements observed with ciclesonide (Omnaris) would make a significant clinical impact.
- There are no direct comparison studies between ciclesonide (Omnaris) and other corticosteroid nasal sprays, and no evidence that ciclesonide (Omnaris) provides any clinical advantage over available alternatives.
- At the recommended dose, ciclesonide (Omnaris) costs $0.80/day, which is more expensive than other corticosteroid nasal sprays currently listed on the Formulary, such as beclomethasone, flunisolide and budesonide.
- Overall, the Committee noted that there is no evidence that ciclesonide (Omnaris) provides any therapeutic advantage over less costly alternatives on the Formulary.

Background:

Allergic rhinitis refers to inflammation of the nasal passages caused by airborne particles such as dust, dander or plant pollen. In people who are allergic to these substances, the immune system produces antibodies to these allergens and cause inflammatory chemicals, such as histamine, to be released locally and into the bloodstream. Symptoms of allergic rhinitis include sneezing, itching, nasal congestion, and runny nose. Patients may also experience symptoms in their eyes, throat and ears. Allergic rhinitis can be seasonal (occurring during specific seasons) or perennial (occurring year round).

The goal of treatment is to control symptoms. The first step is to reduce exposure to allergens and triggers that provoke allergic rhinitis. Drug treatments include corticosteroid nasal sprays, antihistamines, decongestants, cromolyn, saline and immunotherapy (allergy injections).

Detailed Discussion:

No additional details. The full CED discussion is as outlined in the Highlights of Recommendation section.

CEDAC Recommendation:

The Canadian Expert Drug Advisory Committee (CEDAC) recommended that ciclesonide (Omnaris) not be listed.

Executive Officer Decision

Taking into consideration the CED’s recommendation, the Executive Officer decided list ciclesonide (Omnaris) nasal spray on the Ontario Drug Benefit Formulary based on a listing agreement with the manufacturer that addresses price and appropriate utilization.

Status

Funding is available through the Ontario Public Drug Programs.

For more information, please contact:

Ministry of Health and Long-Term Care
Ontario Public Drug Programs

80 Grosvenor Street, Queen’s Park
Toronto, Ontario M7A 1R3

or click: http://www.health.gov.on.ca/english/providers/program/drugs/